Type D Personality as a Cardiovascular Risk Marker in the General Population: Results from the Gutenberg Health StudyManfred E. Beutel, Matthias Michal, Y. Till et al.|Psychotherapy and Psychosomatics|2012Cited by 74
Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular diseaseFranz–Josef Neumann, Karsten Sydow, Stergios Tzikas et al.|Atherosclerosis|2013Cited by 51
Differential Associations of Depressive Symptom Dimensions with Cardio-Vascular Disease in the Community: Results from the Gutenberg Health StudyMatthias Michal, Manfred E. Beutel, Jörg Wiltink et al.|PLoS ONE|2013Cited by 45
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPA‐REG OUTCOME</scp> trial with a focus on AsiaQiuhe Ji, Odd Erik Johansen, Linong Ji et al.|Diabetes Obesity and Metabolism|2021Cited by 25
SAT-305 EFFECTS OF EMPAGLIFLOZIN VS PLACEBO ON CARDIORENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND PROTEINURIC DIABETIC KIDNEY DISEASE: INSIGHTS FROM EMPA-REG OUTCOMEC. Wanner, Sibylle J. Hauske, Bernard Zinman et al.|Kidney International Reports|2019Cited by 5